INTRODUCTION Yttrium 90-ibritumomab tiuxetan (90Y-IT) radioimmunotherapy has proved to be effective in relapsed follicular lymphoma (FL). We conducted a clinical trial in which 90Y-IT followed by maintenance rituximab (MR) was evaluated as initial therapy for high-tumor-burden FL. METHODS Eligible patients had histologically confirmed FL and met the GELF (Groupe d'Etude des Lymphomes Follicul...

(1) Background: New generation of PET-CT scanners allows performing volumetric dosimetry based on 90Y-activity distribution. The aim this study was to perform an up-to-date evaluation the optimal 90Y-PET-CT reconstruction parameters for a Siemens Biograph mCT scanner. (2) Methods: A cylindrical uniform phantom (P1), IEC NEMA Body-phantom (P2) and Torso-phantom (P3) filled with 90Y were acquired...

The increasing incidence of non-Hodgkin's lymphoma (NHL), coupled with the lack of optimal treatment options, has prompted the development of novel treatments. Of these, radioimmunotherapy is one of the most promising. Two of the radiolabeled monoclonal antibody therapies being studied in the treatment of NHL are yttrium 90 (90Y) ibritumomab tiuxetan and iodine 131 (131I) tositumomab. The radio...

Radioisotopes that emit electrons (beta particles), such as radioiodine, can effectively kill target cells, including cancer cells. Aqueous 32P[PO4] is a pure beta-emitter that has been used for several decades to treat non-malignant human myeloproliferative diseases. 32P[PO4] was directly compared to a more powerful pure beta-emitter, the clinically important 90Y isotope. In vitro, 32P[PO4] wa...

Cerenkov counting is a convenient and effective method of high-energy beta radiation, which has long been used to measure number radionuclides, such as, in particular, 90Sr+90Y, environmental objects. The traditional requires the use radiochemical sample preparation procedures, but these procedures may be simpler than those used, for example, liquid scintillation (LSC) method. We proposed Ceren...

Therapeutic trials were performed on the HepG2 human hepatoblastoma implanted s.c. in the athymic nude mouse. Animals were treated with polyclonal and monoclonal antiferritin and control antibodies labeled with either iodine-131 (131I) or yttrium-90 (90Y). Administration of 400 muCi of 131I-labeled polyclonal antiferritin or 300 muCi of 90Y-labeled polyclonal antiferritin significantly increase...

90Sr activity was measured with the full spectrum DPM (FS-DPM) counting method after plotting the quench correction curves of 90Sr and 90Y, and the FS-DPM method was applied to determine the 90Sr in liquid waste samples. The optimum regions of 90Sr and 90Y were set for measuring 90Sr with the dual label DPM (DL-DPM) method. The direct measurement of purified 90Sr with spectrum unfolding techniq...

a 65 year old male with metastatic colorectal cancer (mcrc) in the liver was referred for selective internal radionuclide therapy (sirt) following a history of extensive systemic chemotherapy. 90y pet imaging was performed immediately after treatment and used to confirm lesion targeting and measure individual lesion absorbed doses. lesion dosimetry was highly predictive of eventual response in ...

Tumor-specific anti-idiotype (anti-Id) monoclonal antibodies (MoAbs) to B-cell lymphomas have been administered to patients, resulting in significant clinical responses. However, clinical responses have been limited by the emergence of Id-negative lymphoma. To overcome the problem of tumor heterogeneity, we conducted a pilot evaluation of the safety and effectiveness of yttrium 90 (90Y)-labeled...

In the context of radiopharmacy and molecular imaging, the concept of theranostics entails a therapy-accompanying diagnosis with the aim of a patient-specific treatment. Using the adequate diagnostic radiopharmaceutical, the disease and the state of the disease are verified for an individual patient. The other way around, it verifies that the radiopharmaceutical in hand represents a target-spec...